Built with Alexion, Apellis and Annexon, the 5th Complement-based Drug Development Summit returns for its fifth year as the definitive industrydedicated forum to maximize complement-targeting in the pan-disease setting.
With pivotal clinical readouts poised to be released in 2021, this year's summit will once again unite thought leaders in complement-based drug development.
Expect to be involved in interactive discussions on:
- How dysregulated complement signaling contributes to disease and how to identify novel drug targets up and downstream of C3 and C5
- Preclinical and clinical pipeline progress of diverse drug modalities, including gene therapy approaches, small molecule inhibitors, antibodies, protease inhibitors, nucleic acids and more!
- Leveraging complement proteins in precision-based medicine as disease biomarkers and companion diagnostics
- Addressing clinical challenges of complement-targeted therapeutic sequencing, combinations and timing of administration
- Expanding the clinical utility of complement inhibitors across rare diseases, as well as autoimmune, ophthalmic, neurological and cancer settings
New for this year, you'll have a two-tracked agenda with more speakers, more content and more networking opportunities than ever before! As the growth potential of novel complement-targeting therapeutics becomes apparent, join the conversation to realize the clinical and commercial potential of complement proteins as pan-disease targets!
Running digitally October 26-28, 2021.
Group discounts and early booking rates are available. Please visit the website for full pricing information.
Time: 1:00 pm - 5:00 pm
Conference + 1 Workshop (DRUG DEVELOPER PRICING): USD 2498.00,
Conference Only (DRUG DEVELOPER PRICING): USD 2099.00,
Conference + 1 Workshop (ACADEMIC PRICING): USD 1698.00,
Conference Only (ACADEMIC PRICING): USD 1399.00,
Conference + 1 Workshop (INDUSTRY PRICING): USD 3298.00,
Conference Only (INDUSTRY PRICING): USD 2799.00
Speakers: Tim Higenbottam, Professor, Akari Therapeutics, Anita Hill, Vice President, Global Medical Affairs Lead Haematology and Nephrology, Consultant Clinical Development, Alexion, Moshe Vardi, VP, R&D Global Medicine Team Leader Hematology/Nephrology, Alexion, Shamsah Kazani, Sr. Medical Director Hematology/Nephrology, Alexion, Sanjay Keswani, EVP and Chief Medical Officer, Annexon Biosciences, Lukas Scheibler, Chief Innovation Officer, Apellis, Inge Van de Walle, Principal Scientist, argenx, Yingying Zhang, Postdoctoral Fellow, Boston Children’s Hospital (Michael Carroll’s lab), Paul Morgan, Professor of Immunology, Cardiff University, Daniel Benjamin, Chief Executive Officer, Cascade Biotechnology Inc., Grant Blouse, Senior Vice President, Translational Research, Catalyst Biosciences, Frank Baas, Chief Scientific Officer, Complement Pharma, Sandra Wymann, Senior Manager, Translational Research, CSL Behring AG, Renfeng Guo, Chief Scientific Officer InflaRx N.V., Jesse Hanson, Senior Scientist, Genentech, Inc, Edward F. Patz, Chief Executive Officer, Grid Therapeutics, Ruchi Sharma, Staff Scientist, National Eye Institute/NIH, Stephen Poor, Director External Opportunities and Translational Biomarkers, Novartis Institutes for Biomedical Research, Department of Ophthalmology, Shelia M. Violette, Co-Founder, Chief Scientific Officer and President of Research, Q32 Bio, Michael Storek, Head of Complement Cluster, Sanofi, Curtis Rambaran, VP Head Clinical Science, Silence Therapeutics, Jeffry Lawrence, Interim Vice President, Clinical Development, Solid Biosciences, Petra Duda, Head of Development – Zilucoplan, UCB, Dorothy Schafer, Associate Professor of Neurobiology, UMass Medical School, Hung D. Nguyen, Assistant Professor of Medicine, University of Central Florida College of Medicine, Michael Holers, Professor of Medicine and Immunology, University of Colorado School of Medicine, Dmitri Simberg, Associate Professor, University of Colorado